2020 Volume 32 Issue 1 Pages 48-56
Objective: This study evaluated the differences of clinical performance between 50 mg and 100 mg of golimumab in patients with rheumatoid arthritis
Methods: The clinical background and the changes of disease activity score（DAS28-ESR）were analyzed for 72 patients（36 cases in the 50 mg group, 36 cases in the 100 mg group）who were treated with golimumab for at least three months.
Results: The rates of concomitant use of methotrexate（MTX）were 83.3% in the 50 mg group and 47.2% in the 100 mg group. The mean doses of MTX were 8.3 and 7.2 mg/week respectively. Also, the rates of concomitant use of prednisolone（PSL）were 58.3% in the 50 mg group and 52.7% in the 100 mg group. The mean doses of PSL were 4.4 and 4.2 mg/week respectively. The DAS 28-ESR at baseline were 3.80 in 50 mg group and 4.12 in 100 mg group（n.s.）. The rates of remission at 12 and 24 weeks were 54.9%, 42.3% in the 50 mg group and 64.6%, 73.9% in the 100 mg group. The average differences of DAS 28-ESR from baseline at 12 weeks were -0.75 in the 50 mg group and -1.48 in the 100 mg group, which showed significant difference（p<0.05）.
Conclusion: From our findings, the administration 100 mg of GLM tended to show better clinical efficacy in the early period of treatment.
